Nicox, the international ophthalmic R&D company, appointed Lauren P. Silvernail to its Board of Directors, for a period of four years.
Silvernail brings to Nicox more than 30 years of experience in leading business growth and financial strategies for life science companies, including nine years at ISTA Pharmaceuticals, a commercial ophthalmic company that was acquired by Bausch + Lomb in 2012.
Nicox has also announced that Birgit Stattin Norinder, already Board member of Nicox since 2011, has been re-elected by the Company`s shareholders as a Board member for a period of four years, as well as Michele Garufi to serve another four year term of office.
“Lauren`s operational experience in drug development and ophthalmology will complement Nicox` Board of Directors and her deep knowledge of the global financial markets brings transactional expertise that is a welcome addition,” said Garufi, Chairman and Chief Executive Officer of Nicox. “As we prepare for the anticipated potential approvals of VyzultaTM1 and ZERVIATE2 during Q3 2017, Lauren`s broad background provides us with valuable expertise as we look to grow and advance our business and expand our globally recognized R&D efforts in ophthalmology. We are delighted to add Lauren`s experience in the ophthalmology field and we look forward to her contribution as Nicox continues to grow.”